Radiopharmaceutical

CIRC Announces 2023 Annual Results

Retrieved on: 
Mercoledì, Aprile 17, 2024
Carbon, Medicine in China, Growth, Development, Diagnosis, Technetium, Radiant, BFT, First Prize, National security, National Medical Products Administration, Conference, CIRC, International, Insurance, Safety, Health, Nuclear medicine, Research, XV, Shenzhou, Radiopharmaceutical, Marketing, Clinical trial, Smart, BINE, Patent, EB, Cancer, Bank statement, The Company, Medical imaging

HONG KONG, Apr 17, 2024 - (ACN Newswire) - China Isotope & Radiation Corporation ("CIRC" or the "Company" , together with its subsidiaries, the "Group"; Stock Code: 1763.HK) announces the audited consolidated financial statements of the Group for the year ended 31 December 2023 ("2023" or the "Reporting Period").

Key Points: 
  • HONG KONG, Apr 17, 2024 - (ACN Newswire) - China Isotope & Radiation Corporation ("CIRC" or the "Company" , together with its subsidiaries, the "Group"; Stock Code: 1763.HK) announces the audited consolidated financial statements of the Group for the year ended 31 December 2023 ("2023" or the "Reporting Period").
  • For the year ended 31 December 2023, the Group operated five business segments, namely pharmaceuticals, radioactive source products, irradiation, radiation therapy equipment and related services and other businesses.
  • In 2023, the Group continued to intensify our market development efforts and achieved continued growth in economic efficiency.
  • As of 31 December 2023, the Group had a number of imaging diagnosis and therapeutic radiopharmaceuticals under research and development.

AdvanCell Expands Leadership Team with the Appointment of Christopher Horvath, MS MBA, as Chief Commercial Officer & Chief Operating Officer and Gary Li, PhD, as Chief Strategy Officer

Retrieved on: 
Mercoledì, Maggio 8, 2024
Radiology, Pharmaceutical, Optical, Oncology, Mental Health, Medical Devices, Infectious Diseases, Genetics, Fitness & Nutrition, Clinical Trials, Cardiology, Biotechnology, Alternative Medicine, Health, Practice Management, Managed Care, General Health, Nursing, Medical Supplies, FDA, Diabetes, Surgery, Other Health, Cancer, Commercial, EVP, Johnson & Johnson, Doctor of Philosophy, Janssen, Prostate cancer, SVP, Pfizer, Patient, Translational medicine, Radiopharmaceutical, MBA, Drug discovery, Merck, Management

Chris Horvath, MS, MBA - Chief Commercial and Operating Officer based in Philadelphia.

Key Points: 
  • Chris Horvath, MS, MBA - Chief Commercial and Operating Officer based in Philadelphia.
  • Chris brings nearly two decades of biopharmaceutical oncology expertise spanning drug discovery, commercialization, and corporate leadership, to AdvanCell.
  • Over the past eight years, Chris has been responsible for commercial strategy and leadership, launch preparation and execution, and revenue growth of both clinical-stage and commercial radiopharmaceuticals in oncology.
  • Most recently, at POINT Biopharma, he served as EVP, Commercial and managed cross-functional alliance operations with Lantheus for two clinical-stage assets.

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA® (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development

Retrieved on: 
Mercoledì, Maggio 8, 2024
Biotechnology, Technology, Health, Radiology, Pharmaceutical, Biometrics, Oncology, Health Technology, Software, Artificial Intelligence, Clinical Trials, PSMA, FDA, Safety, Hospital, Siemens Healthineers, Recurrence, PSA, PET, Artificial intelligence, PET/CT, RH, Prostate cancer, Patient, Metastasis, Physician, Radiopharmaceutical, Multimedia, Algorithm, Medical imaging

Siemens Healthineers plans to evaluate the data to enhance its analytics and artificial intelligence (AI)-based algorithms for prostate cancer image quantification and interpretation across its advanced PET/CT imaging software.

Key Points: 
  • Siemens Healthineers plans to evaluate the data to enhance its analytics and artificial intelligence (AI)-based algorithms for prostate cancer image quantification and interpretation across its advanced PET/CT imaging software.
  • Blue Earth Diagnostics has a long-standing relationship with Siemens Healthineers, a leading medical technology company pioneering breakthroughs in healthcare.”
    Dr. Gauden continued, “We are excited to provide these anonymized POSLUMA data from our LIGHTHOUSE trial, for use in enhancing the Siemens Healthineers syngo.via platform.
  • We also plan to make analytical data from the Phase 3 SPOTLIGHT trial of POSLUMA available in the future.
  • The study enrolled 391 patients at clinical sites in the United States and Europe.

ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials

Retrieved on: 
Martedì, Maggio 7, 2024
Biotechnology, Health, Radiology, Pharmaceutical, Clinical Trials, Radiopharmaceutical, Prostate cancer, Cancer, Partnership, The, Patient, Hospital, Medical imaging

Under the terms of the agreement, Nucleus will manufacture ARTBIO’s 212Pb-radiolabeled therapies for its planned Phase I and II clinical trials of its lead program in prostate cancer, AB001, using ARTBIO’s proprietary AlphaDirectTM 212Pb isolation technology.

Key Points: 
  • Under the terms of the agreement, Nucleus will manufacture ARTBIO’s 212Pb-radiolabeled therapies for its planned Phase I and II clinical trials of its lead program in prostate cancer, AB001, using ARTBIO’s proprietary AlphaDirectTM 212Pb isolation technology.
  • AlphaDirectTM is a first-of-its-kind system that delivers highly pure 212Pb from widely available raw materials.
  • 212Pb is an alpha-emitting radioisotope that has gained attention for its potential applications in therapeutic medicine, particularly in targeted alpha radioligand therapy due to the radioisotope’s attractive short half-life and other properties.
  • Preliminary studies of radiopharmaceuticals labeled with 212Pb have been promising, indicating that 212Pb has the potential to address unmet clinical needs.

Ratio Therapeutics Announces the Appointment of Marc Becker as Chief Financial Officer and Chief Operating Officer

Retrieved on: 
Lunedì, Maggio 6, 2024
Financial management, Sale, University, Genzyme, CFO, Sun Pharma, Flagship, Knowledge, IPO, CPA, Senior, CRISPR Therapeutics, Babson College, Radiopharmaceutical, MBA, Therapy, Growth, Strategic planning, Management

BOSTON, May 6, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Marc Becker as the company's Chief Financial Officer and Chief Operating Officer.

Key Points: 
  • BOSTON, May 6, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Marc Becker as the company's Chief Financial Officer and Chief Operating Officer.
  • This appointment will reinforce Ratio's financial and operational leadership by bringing significant experience in biotech and pharma to guide growth strategies and ensure continued success.
  • "We are honored to welcome Marc to the Ratio team," commented Dr. Jack Hoppin, Chairman and Chief Executive Officer of Ratio.
  • "It's a privilege to become part of Ratio's team during this critical juncture, especially with the escalating momentum surrounding the development of targeted radiopharmaceuticals within our industry," said Marc Becker, Chief Financial Officer and Chief Operating Officer of Ratio.

ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial

Retrieved on: 
Martedì, Aprile 23, 2024
Patient, Safety, Hospital, Research, Glioblastoma, Disease, Radiopharmaceutical, Teaching hospital, IIT, ITM, Nuclear medicine, Injection, Pharmaceutical industry

Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster, Helmholtz Munich, and ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that the first patient has been dosed in an investigator-initiated trial (IIT) with ITM’s radiopharmaceutical drug candidate, ITM-31 for the potential use in glioblastoma patients.

Key Points: 
  • Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster, Helmholtz Munich, and ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that the first patient has been dosed in an investigator-initiated trial (IIT) with ITM’s radiopharmaceutical drug candidate, ITM-31 for the potential use in glioblastoma patients.
  • The IIT is sponsored by the University Hospital Münster, conducted in hospitals in Münster, Essen, Cologne, and Würzburg, and supported by Helmholtz Munich and ITM.
  • After glioblastoma patients receive standard treatment with surgery, radio- and chemotherapy, individual tumor cells often remain undetected in surrounding tissue and grow again leading to relapse.
  • Patients will receive their personalized calculated total doses of ITM-31 in three fractions with an interval of 4 weeks between injections.

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

Retrieved on: 
Lunedì, Aprile 15, 2024
FDA, University, Fast Track, Pharmacy, Food and Drug Administration, TLX, NDA, Food, Radiology, MD, ASX, PET, Partnership, Research, Glioma, UCSF, Patient, FET, Radiopharmaceutical, 18F-FET, Diagnosis

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or 18F-FET).

Key Points: 
  • MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or 18F-FET).
  • The granted Fast Track designation is for the characterisation of progressive or recurrent glioma using positron emission tomography (PET).
  • Concurrently, Telix is in the final stages of preparing its U.S. New Drug Application (NDA) for TLX101-CDx in this initial indication, in both adult and paediatric patients.
  • This designation enables expedited review and closer consultation with the FDA during the review process.

Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer

Retrieved on: 
Giovedì, Maggio 2, 2024
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Cancer, RLT, Atlas, Atlas Venture, Doctor of Philosophy, Centerview Partners, Research, Carcinoma, Biomedicine, Science, Biomedical Research, Acquisition, Radiopharmaceutical, Drug discovery, Medical imaging

The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis.

Key Points: 
  • The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis.
  • “Novartis is an established leader in the commercialization of radiopharmaceuticals with a world-class team and global reach.
  • Together, we offer a compelling combination of capabilities,” said Simon Read, Founder and CEO, Mariana Oncology.
  • Centerview Partners LLC served as financial advisor, and Goodwin Procter as legal counsel to Mariana Oncology on the transaction.

ASP Isotopes Issues Letter to Stockholders

Retrieved on: 
Giovedì, Aprile 11, 2024
Consensus, FDA, Nuclear energy, Uranium, Memorandum, Void coefficient, SMR, Intelligence, Prostate cancer, Isotope, ASP, Silicon, Annual report, Yoy, PET, Semiconductor, Private, DOE, Acceleration, Safety, GE HealthCare, Small modular reactor, Artificial intelligence, Coal, Nuclear Energy Institute, Exercise, Isotopes of ytterbium, NEI, Cyclotron, Laser, Radiopharmaceutical, Government, FDG, Silane, Sale, Lithium, Lutetium (177Lu) vipivotide tetraxetan, LEU, Lutetium, Radionuclide, Electronics, ASPI, Letter, Growth, Rare-earth element

WASHINGTON, April 11, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASPI,” or the “Company”), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries, today released the following letter to stockholders from its Chairman and CEO, Paul Mann.

Key Points: 
  • WASHINGTON, April 11, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASPI,” or the “Company”), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries, today released the following letter to stockholders from its Chairman and CEO, Paul Mann.
  • The contract required RC14 to provide an irrevocable standby letter of credit in lieu of a deposit, which was received.
  • Our proprietary technology has proven capabilities to enrich a wide range of isotopes, including light isotopes and lighter molecules, such as silane (SiH4).
  • ASP Isotopes’ goal is to become the lowest cost and most reliable supplier of stable isotopes globally.

NorthStar Appoints Peter Pfreundschuh to Board of Managers

Retrieved on: 
Lunedì, Aprile 15, 2024
Research, Other Health, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, CFO, Cancer, LLP, NorthStar, Johnson & Johnson, Business development, Health technology, Business, Growth, CDMO, Rider University, Sucampo Pharmaceuticals, Patient, SCMP, Radiopharmaceutical, MBA, Therapy, Ernst & Young, Certified Public Accountant, AstraZeneca, Pharmaceutical industry

NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024.

Key Points: 
  • NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024.
  • "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar.
  • “2024 and the next few years will be critical for NorthStar,” said Frank Scholz, NorthStar President and Chief Executive Officer.
  • I look forward to Pete joining the NorthStar Board.”